Enveric Biosciences to Participate in Upcoming Conferences in June 2022
Enveric Biosciences (NASDAQ: ENVB), a biotechnology firm focused on psychedelic-inspired mental health treatments, announced participation in three key conferences: the A.G.P. Summer Healthcare Conference on June 21-22, the Gravitas Los Angeles Summit on June 22, and the H.C. Wainwright Mental Health Conference on June 27. CEO Dr. Joseph Tucker will represent the company at these events, highlighting its commitment to developing innovative solutions for mental health issues affecting patients globally.
- None.
- None.
NAPLES, Fla., June 8, 2022 /PRNewswire/ - Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a neuroscience-focused biotechnology company developing next-generation, psychedelic-inspired mental health medicines, today announced that Dr. Joseph Tucker, Chief Executive Officer of Enveric, will participate in three upcoming conferences:
A.G.P.'s Summer Healthcare Conference
Date: June 21st – 22nd, 2022
Location: Virtual
Gravitas' 3rd Los Angeles Summit
Date: Wednesday, June 22nd at 1:30 p.m. PT
Location: Beverly Hills Hotel in Los Angeles, CA
H.C. Wainwright 1st Annual Mental Health Conference: Neuropsychiatry, Psychedelics, and Beyond
Date: Monday, June 27th, 2022 at 3:30 p.m. ET
Location: Lotte New York Palace Hotel
To attend, please register here.
For more information about the conference, or to schedule a one-on-one meeting with Enveric's management team, please contact your appropriate representatives, or send an email to A.G.P. at agpevents@allianceg.com, Gravitas at events@gravitassecurities.com, H.C. Wainwright at lk@hcwco.com or KCSA Strategic Communications at EnvericBio@kcsa.com.
Enveric Biosciences, Inc. (NASDAQ: ENVB) is a neuroscience-focused pharmaceutical company developing next-generation, psychedelic-inspired mental health medicines. Enveric's robust pipeline supports drug development from the clinic to commercialization aimed to help millions of patients in need around the world suffering from conditions that include cancer-related distress, PTSD and more. For additional information, please visit www.enveric.com.
This press release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. Generally, forward-looking statements and information may be identified by the use of forward-looking terminology such as "plans,"" expects" or "does not expect," "proposed," "is expected," "budgets," "scheduled," "estimates," "forecasts," "intends," "anticipates" or "does not anticipate," or "believes," or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, would, or might occur or be achieved. Forward-looking statements consist of not purely historical statements, including any statements regarding beliefs, plans, expectations, or intentions regarding the future. Such forward-looking statements are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including, but not limited to, the ability of the company to successfully spin-off its cannabinoid assets; the ability to achieve the value creation contemplated by technical developments; the impact of the novel coronavirus (COVID-19) on Enveric's ongoing and planned clinical trials; the geographic, social and economic impact of COVID-19 on Enveric's ability to conduct its business and raise capital in the future when needed; delays in planned clinical trials; the ability to establish that potential products are efficacious or safe in preclinical or clinical trials; the ability to establish or maintain collaborations on the development of therapeutic candidates; the ability to obtain appropriate or necessary governmental approvals to market potential products; the ability to obtain future funding for developmental products and working capital and to obtain such funding on commercially reasonable terms; Enveric's ability to manufacture product candidates on a commercial scale or in collaborations with third parties; changes in the size and nature of competitors; the ability to retain key executives and scientists; and the ability to secure and enforce legal rights related to Enveric's products, including patent protection. A discussion of these and other factors, including risks and uncertainties with respect to Enveric, is set forth in Enveric's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Enveric disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
View original content:https://www.prnewswire.com/news-releases/enveric-biosciences-to-participate-in-upcoming-conferences-in-june-2022-301563603.html
SOURCE Enveric Biosciences
FAQ
What conferences will Enveric Biosciences participate in June 2022?
Who is representing Enveric at the upcoming conferences?
What is the focus of Enveric Biosciences' developments?
When is the H.C. Wainwright Mental Health Conference?
How can investors schedule meetings with Enveric's management during the conferences?
